The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | Timing and patient selection for stem cell transplantation in systemic AL amyloidosis
Patrick Hagen, MD, Loyola University Medical Center, Chicago, IL, discusses patient selection and optimal timing of stem cell transplantation (SCT) for systemic light chain (AL) amyloidosis. Dr Hagen highlights that key factors dictating transplant eligibility also act as prognostic markers. This means that high levels of cardiac enzymes, markers of cardiac stress, and the presence of comorbidities (for example, chronic kidney disease) predict poorer outcomes, even with non-transplant-directed therapies. Dr Hagen also emphasizes that patients should be offered high-dose chemotherapy and transplant as early as possible in their disease journey when fitness is greatest and the patient has fewer comorbidities and a lower likelihood of organ progression. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau Sanofi
